Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Silverback Therapeutics is raising $84,999,995.00 in new funding. Sources indicate as part of senior management Chairman, Peter Thompson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Silverback Therapeutics

Silverback Therapeutics is charting a new path for treating a range of serious diseases representing unmet needs. At the core of our pipeline is our novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administered to patients, but that act only at the sites of disease, sparing healthy tissues from unwanted side effects. Silverback was founded in 2016 and is based in the vibrant South Lake Union neighborhood in Seattle, Washington, where our multi-disciplinary team is rapidly advancing our lead programs toward clinical trials in multiple indications.

To learn more about Silverback Therapeutics, visit http://www.silverbacktx.com/

Contact:
Peter Thompson, Chairman
206-456-2900
https://www.linkedin.com/in/peter-thompson-0b069a1b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved